| scholarly article | Q13442814 |
| P953 | full work available at URL | http://cancerres.aacrjournals.org/cgi/content/abstract/63/17/5559 |
| P698 | PubMed publication ID | 14500395 |
| P50 | author | Jong-In Park | Q63378248 |
| P2093 | author name string | Bruce Ruggeri | |
| Craig Dionne | |||
| Susan Jones-Bolin | |||
| Mark Rosen | |||
| Barry D. Nelkin | |||
| Douglas W. Ball | |||
| Samuel R. Denmeade | |||
| Christopher J. Strock | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| thyroid carcinoma | Q18556131 | ||
| indoles | Q55698578 | ||
| P304 | page(s) | 5559-5563 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth | |
| P478 | volume | 63 |
| Q27851632 | Anti-tumor activity of motesanib in a medullary thyroid cancer model |
| Q39513601 | FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations |
| Q37829880 | FLT3 inhibitors: a story of the old and the new. |
| Q37902072 | How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer |
| Q34274467 | Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). |
| Q39669749 | K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells. |
| Q34021753 | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms |
| Q37022649 | Molecular biology of thyroid cancer initiation. |
| Q37597739 | On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology |
| Q89737237 | Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action |
| Q34055511 | Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma |
| Q39410783 | Protein kinase inhibitors as therapeutic drugs in AML: advances and challenges. |
| Q37979656 | RET TKI: potential role in thyroid cancers. |
| Q40221010 | RET and neuroendocrine tumors |
| Q26860796 | Targeting JAK2 in the therapy of myeloproliferative neoplasms |
| Q34555386 | The Future of Targeting FLT3 Activation in AML. |
| Q50085302 | The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer |
| Q37705695 | Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis |
| Q38208316 | Thyroid Cancer: Role of RET and Beyond |
| Q33760910 | Thyroid cancer: current molecular perspectives |
| Q34636735 | Treatment of FLT3-ITD acute myeloid leukemia. |
| Q36214947 | Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo |
Search more.